Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study

Smouldering multiple myeloma (SMM) is associated with increased risk of progression to multiple myeloma within 2 years, with no approved treatments. Elotuzumab has been shown to promote natural killer (NK) cell stimulation and antibody‐dependent cellular cytotoxicity (ADCC) in vitro. CD56(dim) (CD56...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Haematol
Auteurs principaux: Jagannath, Sundar, Laubach, Jacob, Wong, Ellice, Stockerl‐Goldstein, Keith, Rosenbaum, Cara, Dhodapkar, Madhav, Jou, Ying‐Ming, Lynch, Mark, Robbins, Michael, Shelat, Suresh, Anderson, Kenneth C., Richardson, Paul G.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2018
Sujets:
Haematological Malignancy
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6105456/
https://ncbi.nlm.nih.gov/pubmed/29808907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15384
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires